Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -283.63% is 694% below its 5-year average of -35.74%, near the low end of its 5-year range (-283.63%–59.63%).
128.41% below its 12-month average of -124.17%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -37.88%.
RETURN ON ASSETS (ROA)
-283.63%
RETURN ON ASSETS (ROA) AVG TTM
-124.17%
RETURN ON ASSETS (ROA) AVG 3Y
-74.25%
RETURN ON ASSETS (ROA) AVG 5Y
-35.74%
RETURN ON ASSETS (ROA) AVG 10Y
-158.80%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-128.41%
CURRENT VS 3Y AVG
-282.01%
CURRENT VS 5Y AVG
-693.56%
CURRENT VS 10Y AVG
-78.60%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-27.35%
median of 507 covered companies
CURRENT VS SECTOR MEDIAN
-937.04%
vs the sector median at left
Co-Diagnostics, Inc.
Market Cap
$7.00M
Return on Assets (ROA)
-283.63%
TTM Avg
-124.17%
3Y Avg
-74.25%
5Y Avg
-35.74%
Market Cap
$6.77M
Return on Assets (ROA)
-95.26%
TTM Avg
-176.86%
3Y Avg
-120.19%
5Y Avg
-105.02%
Market Cap
$6.85M
Return on Assets (ROA)
-97.60%
TTM Avg
-274.34%
3Y Avg
-160.93%
5Y Avg
-165.76%
Market Cap
$6.80M
Return on Assets (ROA)
-50.98%
TTM Avg
-191.11%
3Y Avg
-206.10%
5Y Avg
-240.87%
Market Cap
$7.21M
Return on Assets (ROA)
-206.32%
TTM Avg
-53.14%
3Y Avg
-33.03%
5Y Avg
-33.03%
Market Cap
$6.72M
Return on Assets (ROA)
-71.23%
TTM Avg
-61.08%
3Y Avg
-51.04%
5Y Avg
-61.11%
Market Cap
$7.58M
Return on Assets (ROA)
-414.54%
TTM Avg
-226.50%
3Y Avg
-135.75%
5Y Avg
-126.75%
Market Cap
$6.46M
Return on Assets (ROA)
-55.85%
TTM Avg
-69.75%
3Y Avg
-63.38%
5Y Avg
-59.39%
Market Cap
$6.41M
Return on Assets (ROA)
-426.88%
TTM Avg
-139.62%
3Y Avg
-270.47%
5Y Avg
-207.15%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Co-Diagnostics, Inc. (CODX) | $7.00M | -283.63% | -124.17% | -74.25% | -35.74% |
| KALA BIO, Inc. (KALA)vs › | $6.77M | -95.26% | -176.86% | -120.19% | -105.02% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.85M | -97.60% | -274.34% | -160.93% | -165.76% |
| Aclarion, Inc. (ACON)vs › | $6.80M | -50.98% | -191.11% | -206.10% | -240.87% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.21M | -206.32% | -53.14% | -33.03% | -33.03% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -71.23% | -61.08% | -51.04% | -61.11% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.58M | -414.54% | -226.50% | -135.75% | -126.75% |
| Biomerica, Inc. (BMRA)vs › | $6.46M | -55.85% | -69.75% | -63.38% | -59.39% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.41M | -426.88% | -139.62% | -270.47% | -207.15% |
| Longeveron Inc. (LGVN)vs › | $7.61M | -151.57% | -141.88% | -132.44% | -101.65% |
ROA
-283.6%
ROE
-370.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -189.54% |
| 2024-12-31 | -58.81% |
| 2023-12-31 | -37.07% |
| 2022-12-31 | -11.57% |
| 2021-12-31 | 22.91% |
| 2020-12-31 | 59.63% |
| 2019-12-31 | -279.67% |
| 2018-12-31 | -403.80% |
| 2017-12-31 | -149.27% |
| 2016-12-31 | -148.84% |
| 2015-12-31 | -550.82% |
| 2014-12-31 | -403.37% |
